Protara: A Bombed Out Biotech With A Very Positive Skew [Seeking Alpha]
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Seeking Alpha
The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is trading below its cash value, presenting a potential undervaluation opportunity if its phase 2 trials are successful. Protara Therapeutics, Inc. ( NASDAQ: TARA ) is a small-cap biotechnology company with a focus on developing therapies for cancer and rare diseases. Its main candidate TARA-002 is being applied to the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphangiomas (lymphatic malformations) or LM. Both these applications have been moved along by the company to the phase 2 stage of development with some near-term milestones to be had in 2024. In this article, we look at the potential timings for these catalysts and its value for money at its current valuation. The Candidates Protara's main candidate TARA-002 is a cell therapy based on the originator therapy OK-432 which was approved for LM treatm
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing [Yahoo! Finance]Yahoo! Finance
TARA
Earnings
- 3/13/24 - Beat
TARA
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TARA's page on the SEC website